The Efficacy of Renin Angiotensin System Inhibitors (Rasi) in Patients with Coronary Artery Disease without Heart Failure: Systematic Review and Meta-Analysis

Abstract

The benefit is much less clear for stable disease than for acute coronary syndromes. Patients who have
hypertension, diabetes mellitus, a left ventricular ejection fraction of 40% or less, or chronic kidney disease; the aim of this
systematic review and meta-analysis was renin angiotensin system inhibitors in patients with coronary artery disease.
MEDLINE, PubMed, Cochrane Library, Embase, ISI, google scholar were used as electronic databases to perform a
systematic search for relevant articles published in the dental literature between unit 2019. A commercially available
software program (Endnote X9) was used for electronic title management. Searches were performed with keywords,
“angiotensin system inhibitors”, “coronary artery disease”,” heart failure”,” RASi”. All the included studies reported the
effect of RAS inhibitors on mortality. Use of RAS inhibitors was associated with reduced mortality in the pooled analysis
of OCSs with PS analysis (RR [95% CI] = 0.90). Patients with stable coronary artery disease without heart failure, the
current body of evidence from randomized trials shows a significant benefit of RASi for the reduction of cardiovascular
events and all-cause mortality only in comparison with placebo but not with active controls.